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Sedentary lifestyles and energy-rich diets are driving an increasing prevalence of abdominal 
obesity, which is associated with cardiovascular risk. Reliable estimates of the worldwide 
prevalence of abdominal obesity are needed to quantify the associated health risk. The 
International Day for the Evaluation of Abdominal obesity (IDEA) study is a large, 
international epidemiological cross-sectional study designed to provide reliable data on the 
distribution of waist circumference according to region, gender, age, and socio-economic 
level in 177 345 primary care patients from 63 countries across five continents. Any non-
pregnant patient aged 18–80 consulting one of the randomly selected primary care physicians 
on two pre-defined half days was eligible to participate in the study. The primary objective 
was to estimate the prevalence of abdominal obesity in primary care, in each participating 
country. Secondary objectives were to estimate the prevalence of hypertension, type 2 
diabetes, dyslipidaemia, and smoking, and to evaluate their associations with abdominal 
obesity, according to age, gender, and socio-economic level and region. The IDEA study will 
provide the first global map of the prevalence of abdominal obesity and associated 
comorbidities in primary care practice.   
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Introduction   
 
The associations between obesity and an increased risk of the metabolic syndrome, diabetes, 
and cardiovascular disease are well established.1–3 However, there is increasing evidence 
suggesting that abdominal obesity (characterized by intra-abdominal adiposity and high waist 
circumference) is a stronger predictor than generalized obesity [defined by elevated body 
mass index (BMI)] of subsequent development of major coronary events,4–6 vascular 
mortality,4 diabetes,7 and the metabolic syndrome.8 For example, INTERHEART, a case-
control study involving 29 972 participants in 52 countries, showed that the population-
attributable risk of a first myocardial infarction associated with the top two tertiles of waist-
hip ratio, in comparison to the lowest tertile, was 20.1%.6 In addition, an analysis from the 
French Data from an Epidemiological Study on the Insulin Resistance syndrome (D.E.S.I.R.) 
study suggested that the more adverse cardiometabolic risk profile in men, compared with 
women, was largely due to the greater tendency of men to develop abdominal obesity.9 The 
prognostic importance of abdominal obesity is recognized by the inclusion of this parameter 
within the diagnostic criteria of the metabolic syndrome proposed by the US authorities, 10,11 
and in the recent criteria proposed by the International Diabetes Federation (IDF),12 the 
presence of abdominal obesity is a prerequisite for a diagnosis of the metabolic syndrome 
according to the IDF criteria.12   
 
Surveys have demonstrated a high prevalence of abdominal obesity in western populations. 
For example, the prevalence of abdominal obesity in the US men (waist circumference >102 
cm) and women (waist circumference >88 cm) was 36 and 52%, respectively, in 1999–2000, 
and had increased from 30 and 46%, respectively, in 1988–1994.13 In European men and 
women, abdominal obesity defined according to locally defined waist criteria (using cut-off 
values between 90 and 102 cm for men and 80 and 92 cm for women) was 8 and 18%, 
respectively in Greenland,14 21 and 24% in Belgium,15 8 and 13% in France,16 23 and 65% in 
Spain,17 and 18 and 39% in Turkey.18 Even higher rates of abdominal obesity were found in 
primary care populations. In the recent nationwide Diabetes Cardiovascular Risk Evaluation: 
Targets and Essential Data for Commitment of Treatment (DETECT) study of 55 518 
consecutive German primary care attendees, 43% of male and 53% of female patients met 
criteria for abdominal obesity (waist circumference ≥102 for men and ≥88 for women).19 The 
developing world has not been spared the burden of abdominal obesity, with estimated 
prevalence rates (men and women) of 21 and 42% in South Korea,20 26–41% and 21–54% in 
different ethnic groups in Singapore,21 and 35% in women in an urban centre in China.22 
Recent data from Cameroon, Africa, have described a prevalence of abdominal obesity of 
18% in men (waist circumference >94 cm) and 66% in women (waist circumference >80 
cm).23 An increasing trend towards urbanization of populations in the developing world is 
driving increased obesity rates in these nations.24–27   
 
Thus, abdominal obesity poses a major and increasing challenge to health worldwide. 
Although the studies described earlier attest to the potential magnitude of the problem posed 
by abdominal obesity, reliable data estimates are not available for all countries: many studies 
have been based on small sample sizes, the methodology and diagnostic criteria for measuring 
abdominal obesity differ, and few data are available from the primary care setting.   
 
Against this background, the International Day for the Evaluation of Abdominal obesity 
(IDEA) study was carried out to provide global and region-specific estimates of the 
prevalence of abdominal obesity in primary care populations, and its associated comorbidities, 
using consistently applied criteria and methods. Here, we report the rationale and design of 
the study.   
 
 
Design of the IDEA study   
 
Objectives   
 
The primary objective of the IDEA study was to estimate the prevalence of abdominal obesity 
in an unselected population of consecutive patients consulting a randomly selected sample of 
primary care physicians on two prespecified half-days. Secondary objectives were (i) to 
estimate the prevalence of cardiovascular risk factors (hypertension, type 2 diabetes, 
dyslipidaemia, and smoking) and (ii) to study the association between abdominal obesity and 
these conditions (risk factors).   
 
Organization   
 
The IDEA study is a large, international epidemiological cross-sectional study, conducted in 
63 countries across five continents (Figure 1). A Steering Committee of international experts 
in cardiometabolic care oversaw the study (see Acknowledgements), and their responsibilities 
included the design of the data collection form, the design of appropriate methodology to 
ensure a representative sample of primary care physicians and their patients, operational 
guidelines for communication with physicians and patients, and data quality. Three members 
of the Steering Committee served as an Executive Steering Committee, and were responsible 
on behalf of the Steering Committee, for day-to-day operational decisions required during the 
conduct of the study. National co-ordinators administered the study in individual countries, 
and were responsible for interactions with individual physicians.   
 
Participants: patients   
 
All patients aged between 18 and 80 consulting their primary care physician on the pre-
specified two half-days were asked for informed consent and invited to participate, 
irrespective of their reason for consultation. Women with known pregnancy were excluded. A 
booklet given to patients provided easy-to-read information on the study objectives and the 
background of the study.   
 
Participants: physicians   
 
Random selection of physicians   
The IDEA Study was designed to ensure recruitment of a representative sample of patients 
consulting their primary care physician. To achieve this, a random sample of primary care 
physicians representing all geographic areas in each participating country was recruited 
(Figure 2). Within most countries, an exhaustive list of all actively practising primary care 
physicians was compiled, together with their contact details, location, and type of practice 
(e.g. office, hospital, etc.). This initial list was split into geographical areas, according to the 
most commonly-used administrative boundaries used within each country, and a target 
number of physicians within each area was defined.   
 
Central management of the randomization process in most countries was conducted by 
experienced specialist commercial research organizations [Intercontinental Marketing 
Services (IMS) or Centre de Gestion des Données Informatiques Médicales (Cegedim)]. In 
countries where random selection of physicians was managed by IMS, the list of physicians 
was grouped and sorted according to geographical location. A random start number for 
recruitment was defined within the list, and every nth physician on the list from this start point 
was contacted (the primary contact list). If a physician declined to participate, the next 
physician on the list was contacted, and then the following one if that physician declined to 
participate, and so on. The value of n was set to allow sufficient reserve physicians, on the 
basis of reasonable assumptions regarding willingness to participate. In this way, one contact 
list was constructed to ensure a random sample of participating physicians. Countries in 
which physician recruitment was managed by Cegedim employed a randomization procedure 
based on Floyd’s ordered hash table algorithm for simple random sampling,28,29 to provide a 
rapid and efficient method for handling large data sets within SAS analysis software.   
 
In some countries (Table 1), the randomization process was managed locally, after 
implementing stringent quality assurance standards. In China, for example, all patients were 
seen within the hospital setting, and the randomization process involved selection of three 
urban hospitals (one each from primary-care, secondary-care, and tertiary-care hospitals) and 
one hospital from a rural village or town, and one rural county hospital. Identical standards for 
quality assurance of databases of local physicians were applied for central and local 
randomizations to ensure consistency in the recruitment of physicians between countries. 
Procedures for generating an exhaustive list of primary care physicians, the definition of 
regions within each country, statistical procedures relating to the randomization, and the 
generation of lists of participating physicians were supervised by the National Coordinator 
and the Steering Committee. Standard software packages were used for data entry, data 
management, and analyses.   
 
Material provided for physicians   
Participating physicians were provided with the IDEA study protocol, data collection forms, 
and a poster for display in their practice designed to provide information for patients about the 
study. In addition, participating doctors were trained in the measurement of anthropometric 
variables. Booklets were provided in local languages for physicians, providing practical 
information necessary for the administration of the study and background information on 
abdominal obesity, and the associated metabolic and cardiovascular risks (contact H.-U.W. 
for a copy of this material). Physicians were also provided with a standardized method for 
waist circumference measurement, as follows: ‘Waist will be measured at the midpoint 
between the lower rib margin and the iliac crest in centimetres. A point mid-way between the 
lowest rib and the iliac crest will be identified. The metric tape will be held firmly in an 
horizontal position and will be placed around the waist. It is recommended that the observer 
sits beside the participant while the readings are taken. The tape should be loose enough to 
allow the recorder to place one finger between the tape and the subject’s body. Subjects will 
be asked to breathe normally and the time of reading is taken at the end of a normal 
exhalation, while ensuring that the subject does not contract the abdominal muscles.’   
 
Sample size determination   
 
Sample size requirements were determined at the country level. On the assumption that the 
expected prevalence of abdominal obesity among patients visiting a primary care physician is 
likely to be about 50%, the number of patients included in primary care practice should be 
between 1100 and 9600 per country, in order to estimate this prevalence with a precision of 
1–3%. Accordingly, the number of physicians required in each country depended on the 
numbers of patients seen each day. The initial recruitment goal based on these considerations 
was to enrol at least 123 000 patients under the care of at least 7600 primary care physicians 
in 63 countries.   
 
Data collection   
 
Data were collected on two pre-specified half-days, between 9 May and 6 July 2005. The 
same days were used in each country, and were chosen to avoid public holidays, religious 
festivals, times when patients were likely to be on vacation, etc. The following variables were 
assessed by use of a standardized data collection form. Waist circumference (cm), height 
(cm), and body weight (kg) were measured and recorded for all participants. In addition, 
demographic data were collected on gender, year of birth, highest level of education (less than 
high school, high school, college/university, or postgraduate), and profession (employed, 
unemployed or student, retired, or unable to work). Smoking status (never, current, or former) 
and the presence or absence of known cardiovascular risk factors, defined as existing 
cardiovascular disease (coronary heart disease, stroke, or prior revascularization), 
dyslipidaemia, hypertension, or diabetes (type 1 or 2) were also recorded. These data were 
reported by the physicians who were not required to provide documentation to validate their 
diagnostic decisions. A further question recorded whether or not women were post-
menopausal, and if so, whether they were receiving hormone replacement therapy.   
 
On-site quality assurance procedures were conducted by qualified personnel, for random 
selections of 10 patients attending 5% of the study sites. Patient data collection forms were 
divided into two parts: the main area for data collection and a counterfoil, each of which 
identified each patient by a unique number. These were separated after completion of data 
collection for a given patient; the counterfoil was retained at the study site, while the main 
part of the forms was taken to the central data processing site. Study personnel contacted 
investigators by telephone and verified the accuracy of material relating to patients’ age and 
gender. Quality control procedures were completed within 5 days of receiving data collection 
forms from study sites nominated for inclusion in the quality control procedure.   
 
Statistics   
 
All data were processed centrally at a single site designated for this purpose. Data on 
demography, obesity, central adiposity, and cardiovascular risk factors will be summarized 
using descriptive statistics. National estimates of the prevalence of abdominal obesity will be 
given according to criteria proposed for the US (National Cholesterol Education 
Program/Adult Treatment Panel III),10 the Asian-Pacific region (World Health 
Organization/International Association for the Study of Obesity/International Obesity Task 
Force),30 and according to the recent criteria for the metabolic syndrome from the IDF.12 Age 
and sex standardized prevalences, using the age distribution of the total sample separately for 
each sex, will allow comparisons of the frequency of abdominal adiposity between countries 
and regions. Factors associated with abdominal obesity will be explored using multivariate 
analyses. Statistical analyses will be performed at the 5% significance level, using two-sided 
tests or two-sided confidence intervals.   
 
Ethics   
 
The study was conducted according to the principles laid down in the 18th World Medical 
Assembly (Helsinki, 1964) and all subsequent amendments, and in accordance with the 
guidelines for Good Epidemiology Practice. All countries obtained ethical approval for the 
study from their local Ethics Committees. Patients provided written informed consent in the 
presence of the physician. Consent forms were translated into local languages and adapted to 
comply with local data protection requirements where necessary. No information was 
recorded that could be used to identify an individual patient.   
 
Physicians and patients in the IDEA study   
 
Table 1 shows the number and proportions of physicians and patients participating in the 
IDEA study, in each of the 63 countries, by region. On average, of 21 100 eligible physicians 
contacted, 6407 (30%) participated; doctors’ participation rates ranged between 4 and 77%, 
although physician participation rates below 10% occurred in only four countries. Of 182 970 
patients screened, 177 345 patients participated, resulting in a total response rate of 97%. 
Patient participation rates by region (as defined in Table 1) ranged from 84% of patients 
screened (Canada) to 99% of patients screened (Latin America and South Asia).   
 
 
 
Discussion   
 
The IDEA programme will provide the first worldwide estimates of the prevalence of 
abdominal obesity in the primary care setting, using consistently applied methodology and 
criteria. These data will assist greatly in quantifying the magnitude of the threat to individuals 
and healthcare systems from the increasing prevalence of this condition and its associated 
comorbidities. The inclusion of waist measurement as well as data necessary to calculate BMI 
(body weight and height) is an important feature of the design of IDEA, as abdominal obesity 
characterized by high waist circumference appears to provide prognostic data beyond BMI. 
The large size of the survey will also allow for exploration of better thresholds for waist 
circumference with regard to abdominal obesity in men and women of different ages and in 
different countries. It is important to remember, however, that IDEA will provide reliable 
estimates of abdominal obesity prevalence and associated cardiometabolic risk factors that are 
relevant only to users of primary care services. This population is likely to have a higher 
degree of comorbidity as well as a larger waist circumference than nationally representative 
samples from the general population in a given country.   
 
Analyses from the Nurses’ Health Study showed that increasing waist circumference was 
associated with an increasing risk of coronary heart disease irrespective of BMI.5 After 
multivariate adjustment for BMI, a waist circumference >96.5 cm was associated with a 
relative risk of coronary heart disease of 3.06 (95% CI 1.54–6.10). A further analysis from 
this study demonstrated an increased risk of developing diabetes in subjects with abdominal 
obesity [relative risk for 90th vs. 10th centile for waist circumference of 5.1 (2.9–8.9)].7 
Increased secretion by intra-abdominal adipocytes of a range of bioactive substances, 
including free fatty acids, pro-inflammatory mediators, together with decreased secretion of 
adiponectin from these cells, may adversely influence overall cardiometabolic risk either 
directly or indirectly via promotion of insulin resistance.31–33   
 
The measurement of waist circumference is also suitable for use in evaluating patients for 
cardiovascular interventions in routine clinical practice. The high rate of participation in the 
study illustrates the readiness of patients to have their waist circumference measured in 
general practice. For the primary care physician, the simultaneous presence of high waist 
circumference and an additional cardiovascular risk factor, such as hypertriglyceridaemia or 
hyperglycaemia will facilitate the identification of patients likely to have the insulin 
resistance-driven atherogenic triad of elevated ApoB, hyperinsulinaemia, small dense LDL.34 
The data on the prevalence of abdominal obesity and related cardiovascular risk factors from 
IDEA will serve as a useful educational tool in communicating the value of this simple 
technique to physicians.   
 
Conclusions   
 
The IDEA study will provide the first global map of the prevalence of abdominal obesity in 
primary care practice, as indicated by high waist circumference, along with its associated 
comorbidities. Further, these data will illustrate the importance of abdominal obesity as a risk 
factor for cardiovascular disease and type 2 diabetes beyond BMI.   
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Appendix   
 
Members of the IDEA Steering Committee were: B.B.a (France); J.-P.D.a (Canada); S.H.a (USA); Phil 
Barter (Australia); Jean-Pierre Bassand (France); John E. Deanfield (UK); Keith Fox (UK); Luc Van 
Gaal (Belgium); Chee-Eng Tan (Singapore); H.-U. W. (Germany); Sydney Smith (USA).   
 
a Members of the Executive Steering Committee. 
 
IDEA National Coordinators were as follows. Argentina: CP Lau; Australia: M Nelson; Austria: E 
Rebhandl; Belgium: G De Backer; Brazil: A Avezum; Bulgaria: S Zaharieva; Canada: A Sharma; 
Chile: S Kunstmann; China: WU Yang Feng; Colombia: A Ruiz; Czech Republic: V Hainer; 
Denmark: OL Svendsen; Dominican Republic, Jamaica, Trinidad and Tobago: A Gonzalez Medina; 
Ecuador: M Pasquel; Egypt: M Ibrahim; Estonia: M Vigimaa; Finland: M Savolainen; France: P 
Amouyel; Germany: HU Wittchen; Greece: S Raptis and D Kremastinos; Guatemala: MA Rodas; 
Hong Kong: C-P Lau; Hungary: L Halmy; India: A Misra; Indonesia: S Soegondo; Ireland: V Maher; 
Israel: Avraham Porath; Italy: M Carrruba; Korea: H-J Yoo; Latvia: A Kalveli and G Bahs; Lithuania: 
V Kasiulevicius; Malaysia: MZ Morad and R Zambahari; Mexico: AL Esqueda; Morocco: C 
Abdelkhirane; Norway: T Pedersen; Pakistan: A Jabbar; Peru: R Gamboa; Philippines: ML Abrahan; 
Poland: K Narkiewicz; Portugal: V Gil; Russia: RG Oganov; Saudi Arabia: M Halawa; Singapore: ES 
Tai; Slovakia: A Dukát; Slovenia: I Švab; South Africa: M-T van der Merwe; Spain: B Moreno and F 
Casanueva; Sweden: Å Sjöholm; Switzerland: R Darioli, A Gallino, and G Noll; Taiwan: CJ Chang; 
Thailand: P Sritara; The Netherlands: FLJ Visseren; Tunisia: A Belhani; Turkey: V Sansoy; UAE, 
Kuwait, and Qatar: A Binbrek; Ukraine: A Parkhomenko; Venezuela: A Perez Monteverde.   
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